{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000066","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.399578+00:00","generated_at":"2026-06-24T06:06:29.808317+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics and Menarini collaborate for Phase 1b/2 trial of ONA-XR + elacestrant in ER+/PR+ HER2- mBC","bullets":["Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.","Menarini supplies elacestrant at no cost; Context sponsors and funds the study.","Elacestrant Phase 3 showed 30% reduction in risk of progression or death vs SOC in ER+/HER2- mBC.","12-month PFS rate: 22% for elacestrant vs 9% for SOC in overall population.","Preclinical data suggest dual ER and PR blockade may enhance tumor control."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000066","json":"https://secwatch.observer/filing/0001842952-22-000066.json","markdown":"https://secwatch.observer/filing/0001842952-22-000066.md","text":"https://secwatch.observer/filing/0001842952-22-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/0001842952-22-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/cntx-20220801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:06:29.808317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}